GlassScriptPhysician profile
Phyllis A Correia
NPI 1164576930
$3,286.73
in general payments reported to CMS, 2019-2025
23 companies · $91.42 in 2025
The $91.42 reported for 2025 was more than what a typical Advanced Practice Midwife provider received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $906 · 2023: $993 · 2024: $327 · 2025: $91.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.96 | 2022-2025 | |
| Agile Therapeutics, INC. | $318.57 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $286.55 | 2021-2024 | Slynd |
| Myovant Sciences INC. | $247.05 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $232.65 | 2022-2023 | Quviviq |
| Mylan Pharmaceuticals INC. | $225.16 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $225.09 | 2021-2023 | |
| Therapeuticsmd, INC. | $200.70 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $180.41 | 2023-2025 | Myfembree, Gemtesa |
| Abbott Laboratories | $125.00 | 2023 | Freestyle Libre 2 |
| Evofem Biosciences, INC. | $108.83 | 2021-2022 | |
| Glaxosmithkline, LLC. | $107.83 | 2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $102.66 | 2021-2024 | Veozah |
| Lilly USA, LLC | $62.82 | 2024 | Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $59.31 | 2021-2024 | Gardasil, Gardasil 9 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.48 | 2024 | Airsupra, Farxiga |
| Medicem INC. | $46.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.76 | 2022 | |
| Pfizer INC. | $40.26 | 2022-2023 | |
| Novo Nordisk INC | $32.76 | 2025 | Ozempic |
| Sage Therapeutics, LLC | $27.82 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.68 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Correia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.